Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Depreciation and Depletion (2022 - 2026)

Unicycive Therapeutics filings provide 3 years of Depreciation and Depletion readings, the most recent being $7000.0 for Q4 2024.

  • On a quarterly basis, Depreciation and Depletion rose 133.33% to $7000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $22000.0, a 144.44% increase, with the full-year FY2025 number at $34000.0, up 54.55% from a year prior.
  • Depreciation and Depletion hit $7000.0 in Q4 2024 for Unicycive Therapeutics, up from $6000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $9000.0 in Q1 2024 to a low of $1000.0 in Q3 2022.
  • Median Depreciation and Depletion over the past 3 years was $2000.0 (2022), compared with a mean of $3454.5.
  • Biggest five-year swings in Depreciation and Depletion: changed 0.0% in 2023 and later skyrocketed 350.0% in 2024.
  • Unicycive Therapeutics' Depreciation and Depletion stood at $2000.0 in 2022, then soared by 50.0% to $3000.0 in 2023, then surged by 133.33% to $7000.0 in 2024.
  • The last three reported values for Depreciation and Depletion were $7000.0 (Q4 2024), $6000.0 (Q3 2024), and $9000.0 (Q1 2024) per Business Quant data.